当前位置: 首页 > 期刊 > 《新医学》 > 20193
编号:13561085
老年HFpEF患者性别和BMI与甲状腺激素的相关性研究(4)
http://www.100md.com 2019年3月1日 《新医学》 20193
     [4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014. 中华心血管病杂志,2014,42(2):98-122.

    [5] Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B, Boineau R, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Lewis EF, Markov V, O’Meara E, Kobulia B, Shaburishvili T, Solomon SD, Pitt B, Pfeffer MA, Li R. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail,2013,6(2):184-192.

    [6] 梁景強,梁桥安,李财润.曲美他嗪对舒张性心力衰竭患者血管内皮功能及血浆脑钠肽水平的影响. 新医学,2011,42(6):386-388.

    [7] 王洁妤,华琦.左心室射血分数保留的心力衰竭研究进展.中华老年心脑血管病杂志,2016,18(7):766-769.

    [8] Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of national heart,lung,and blood institute. Circulation,2009,119(24):3070-3077.

    [9] 曾桂芳,刘彦杉,郭莹.女性射血分数保留心力衰竭临床特点及诊断.中国医师杂志,2018,20(1):155-158.

    [10] Martinez F. Thyroid hormones and heart failure. Heart Fail Rev, 2016, 21(4):361-364.

    [11] 刘冰.促甲状腺激素对心力衰竭患者预后的影响.当代医学,2016,22(27):21-22.

    [12] Westerink J, van der Graaf Y, Faber DR, Visseren FL; SMART study group. The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease. Eur J Clin Invest,2011, 41(2):159-166.

    [13] Radetti G, Kleon W, Buzi F, Crivellaro C, Pappalardo L, di Iorgi N, Maghnie M. Thyroid function and structure are affected in childhood obesity. J Clin Endocrinol Metab,2008,93(12):4749-4754.

    (收稿日期:2018-12-10)

    (本文编辑:杨江瑜), 百拇医药(栗媛 张丽华 李小威 蒋友旭 牛少辉 潘壮 许慧艳)
上一页1 2 3 4